Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma: Open-label, Multicenter, Randomized, Phase 2 Trials
Latest Information Update: 29 Jul 2025
At a glance
- Drugs Pazopanib (Primary) ; Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
Most Recent Events
- 18 Dec 2024 Status changed from not yet recruiting to recruiting.
- 16 Jan 2023 New trial record